MINIMUM bio specializes in accelerating drug target identification for the pharmaceutical industry, aiming to enhance drug discovery processes and reduce the time and costs associated with preclinical research and development. We specialise in the discovery of molecular glues and new drug targets.

Why work with us

There are several drug target identification platforms such as MS-based pulldowns, genome wide CRISPR-Cas9 and shRNA screens that are generally expensive and time consuming and have blind spots such as low abundance proteins or cascade effects. MINIMUM bio has perfected the application of an antibody discovery platform for drug target discovery. Our Mercurious^® platform is fast, agnostic and iterative allowing us to identify new drug targets for any bioactive molecule in as little as a week at a fraction of the cost for competing technologies. The system works equally well for small molecules, biologics and molecular glues.